Actively recruiting interventional trials in lung cancer.
|Clinical trial investigators and sponsors|
Role of Clinical Trial Investigators and Sponsors
Role of Nonpharmaceutical Funders
Impact of COVID-19: findings from a GLCC members survey.
Role of Regulatory Agencies
CRediT Authorship Contribution Statement
- Actively recruiting interventional trials in lung cancer.Accessed January 3, 2022)
- Global cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.CA Cancer J Clin. 2021; 71: 209-249
- “When Offered to Participate”: a systematic review and meta-analysis of patient agreement to participate in cancer clinical trials.J Natl Cancer Inst. 2021; 113: 244-257
- PL02.09 International Association for the Study of Lung Cancer (IASLC) study of the impacts of COVID-19 on international lung cancer clinical trials.J Thorac Oncol. 2021; 16: S847-S848
- New benchmarks characterizing growth in protocol design complexity.Ther Innov Regul Sci. 2018; 52: 22-28
- Systematic review and meta-analysis of the magnitude of structural, clinical, and physician and patient barriers to cancer clinical trial participation.J Natl Cancer Inst. 2019; 111: 245-255
- Beyond the lessons learned from the COVID-19 pandemic: opportunities to optimize clinical trial implementation in oncology.ESMO Open. 2021; 6: 100237
- Rethinking cancer clinical trial conduct induced by COVID-19: an academic center, industry, government, and regulatory agency perspective.Cancer Discov. 2021; 11: 1881-1885
- COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials.Nat Rev Clin Oncol. 2021; 18: 313-319
- Contribution of NIH funding to new drug approvals 2010-2016.Proc Natl Acad Sci U S A. 2018; 115: 2329-2334
- Impact of COVID-19: findings from a GLCC members survey.https://www.lungcancercoalition.org/2020/06/19/impact-of-covid-19-findings-from-a-glcc-members-survey/Date accessed: September 21, 2021
- Cuts in cancer research funding due to COVID-19.Lancet Oncol. 2021; 22: e6
- Rethinking cancer clinical trials for COVID-19 and beyond.Nat Cancer. 2020; 1: 568-572
Disclosure: Dr. Roy has received institutional research funding from AstraZeneca, Eli Lilly, Merck, Blueprint Medicine, Genentech, G1 Therapeutics, Takeda, Bristol-Myers Squibb , and Janssen not related to the current project. Dr. Baird has received institutional support funding from Amgen, AstraZeneca, Bayer, Blueprint Medicines, Bristol-Myers Squibb, Boehringer Ingelheim, Daiichi Sankyo, Eli Lilly , Merck , Merck Sharp & Dohme , Novartis , Pfizer , Regeneron, Roche, Sanofi, and Takeda not related to the project; has served as consultant for Janssen (honorarium received by organization) and for Roche (Dublin, Ireland). Dr. Ciupek has been consultant for Novartis, GRAIL Inc., and advisory board member for Novartis, Daiichi Sankyo, AstraZeneca, and Foundation Medicine. Dr. Fox has received institutional funding from AstraZeneca, Boehringer Ingelheim, Pfizer , Bristol-Myers Squibb , Amgen, Novartis , Eli Lilly , Merck , Takeda, and Roche not related to the project and participated in advisory boards for Boehringer Ingelheim, Bristol-Myers Squibb, AstraZeneca, Novartis, Debiopharm, and Takeda. Dr. Scagliotti received honoraria from AstraZeneca, Eli Lilly, Merck Sharp & Dohme, Pfizer, Roche, Johnson & Johnson, Takeda; consulting or advisory role for Eli Lilly, BeiGene, and AstraZeneca; received institutional research funding from Eli Lilly and Merck Sharp & Dohme; and received travel, accommodations from Bayer, all not related to the current project. Dr. Mitsudomi received advisory/lecture fees from AstraZeneca , Novartis , Chugai, Boehringer Ingelheim, Pfizer , Roche, Merck Sharp & Dohme, Thermo Fisher, Roche diagnostics, Bristol-Myers Squibb, Ono Pharmaceutical, Taiho, Takeda, Amgen, Johnson and Johnson, Janssen pharma, Puma, BeiGene, Bridge Biotherapeutics, Eli Lilly, Daiichi Sankyo, and Thermo Fisher; research funding from AstraZeneca, Chugai, Boehringer Ingelheim, Pfizer, Taiho, Ono Pharmaceutical, Merck Sharp & Dohme, Daiichi Sankyo, Eli Lilly, Ethicon, and Bridge Biotherapeutics not related to this project. Dr. Bunn has received consulting income from AstraZeneca, Ascentage, Bristol-Myers Squibb, C-Stone, Imidex, Merck, and Verastem not related to this project. Dr. Smeltzer has worked as a paid research consultant for the Association of Community Cancer Centers. The remaining authors declare no conflict of interest.
Cite this article as: Roy UB, Baird AM, Ciupek A, et al. Impact of the coronavirus disease 2019 pandemic on global lung cancer clinical trials: why it matters to people with lung cancer. JTO Clin Res Rep. 2022;3:100269.
User LicenseCreative Commons Attribution – NonCommercial – NoDerivs (CC BY-NC-ND 4.0) |
For non-commercial purposes:
- Read, print & download
- Redistribute or republish the final article
- Text & data mine
- Translate the article (private use only, not for distribution)
- Reuse portions or extracts from the article in other works
- Sell or re-use for commercial purposes
- Distribute translations or adaptations of the article
Elsevier's open access license policy